ARCT to seek Q4 go/no-go for CF inhaled mRNA Phase III
ARCT said Q4 will bring a go/no-go decision on advancing its cystic fibrosis inhaled mRNA therapy to Phase III, alongside imminent Phase II data and OTC deficiency program regulatory updates. The plan cites a $40M Thermo Fisher agreement.